Research ArticleArticle
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate
Gurjit S. Kaeley, Daryl K. MacCarter, Aileen L. Pangan, Xin Wang, Jasmina Kalabic and Veena K. Ranganath
The Journal of Rheumatology September 2018, jrheum.171232; DOI: https://doi.org/10.3899/jrheum.171232
Gurjit S. Kaeley
From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. This study was funded by AbbVie Inc., which manufactures adalimumab. GSK received research funds from AbbVie. VKR received grants from Bristol-Myers Squibb, Genentech, Mallinckrodt, Pfizer, and Rheumatology Research Foundation. DKM is a consultant and has served as a principal investigator for AbbVie. ALP, XW, and JK are AbbVie employees and may hold AbbVie stock or stock options. G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. Address correspondence to Dr. V.K. Ranganath, UCLA Division of Rheumatology, Rehabilitation Building, 1000 Veteran Avenue, Rm 32-59, University of California at Los Angeles, Los Angeles, California 90095, USA. E-mail: vranganath@mednet.ucla.edu. Accepted for publication April 20, 2018.
Daryl K. MacCarter
From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. This study was funded by AbbVie Inc., which manufactures adalimumab. GSK received research funds from AbbVie. VKR received grants from Bristol-Myers Squibb, Genentech, Mallinckrodt, Pfizer, and Rheumatology Research Foundation. DKM is a consultant and has served as a principal investigator for AbbVie. ALP, XW, and JK are AbbVie employees and may hold AbbVie stock or stock options. G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. Address correspondence to Dr. V.K. Ranganath, UCLA Division of Rheumatology, Rehabilitation Building, 1000 Veteran Avenue, Rm 32-59, University of California at Los Angeles, Los Angeles, California 90095, USA. E-mail: vranganath@mednet.ucla.edu. Accepted for publication April 20, 2018.
Aileen L. Pangan
From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. This study was funded by AbbVie Inc., which manufactures adalimumab. GSK received research funds from AbbVie. VKR received grants from Bristol-Myers Squibb, Genentech, Mallinckrodt, Pfizer, and Rheumatology Research Foundation. DKM is a consultant and has served as a principal investigator for AbbVie. ALP, XW, and JK are AbbVie employees and may hold AbbVie stock or stock options. G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. Address correspondence to Dr. V.K. Ranganath, UCLA Division of Rheumatology, Rehabilitation Building, 1000 Veteran Avenue, Rm 32-59, University of California at Los Angeles, Los Angeles, California 90095, USA. E-mail: vranganath@mednet.ucla.edu. Accepted for publication April 20, 2018.
Xin Wang
From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. This study was funded by AbbVie Inc., which manufactures adalimumab. GSK received research funds from AbbVie. VKR received grants from Bristol-Myers Squibb, Genentech, Mallinckrodt, Pfizer, and Rheumatology Research Foundation. DKM is a consultant and has served as a principal investigator for AbbVie. ALP, XW, and JK are AbbVie employees and may hold AbbVie stock or stock options. G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. Address correspondence to Dr. V.K. Ranganath, UCLA Division of Rheumatology, Rehabilitation Building, 1000 Veteran Avenue, Rm 32-59, University of California at Los Angeles, Los Angeles, California 90095, USA. E-mail: vranganath@mednet.ucla.edu. Accepted for publication April 20, 2018.
Jasmina Kalabic
From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. This study was funded by AbbVie Inc., which manufactures adalimumab. GSK received research funds from AbbVie. VKR received grants from Bristol-Myers Squibb, Genentech, Mallinckrodt, Pfizer, and Rheumatology Research Foundation. DKM is a consultant and has served as a principal investigator for AbbVie. ALP, XW, and JK are AbbVie employees and may hold AbbVie stock or stock options. G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. Address correspondence to Dr. V.K. Ranganath, UCLA Division of Rheumatology, Rehabilitation Building, 1000 Veteran Avenue, Rm 32-59, University of California at Los Angeles, Los Angeles, California 90095, USA. E-mail: vranganath@mednet.ucla.edu. Accepted for publication April 20, 2018.
Veena K. Ranganath
From the Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine, Jacksonville, Florida; Department of Rheumatology, North Valley Hospital, Whitefish, Montana; Global Medical Affairs, AbbVie Inc., North Chicago, Illinois; Data and Statistical Sciences, AbbVie Inc., North Chicago, Illinois; Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA; Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany. This study was funded by AbbVie Inc., which manufactures adalimumab. GSK received research funds from AbbVie. VKR received grants from Bristol-Myers Squibb, Genentech, Mallinckrodt, Pfizer, and Rheumatology Research Foundation. DKM is a consultant and has served as a principal investigator for AbbVie. ALP, XW, and JK are AbbVie employees and may hold AbbVie stock or stock options. G.S. Kaeley, MD, Division of Rheumatology and Clinical Immunology, University of Florida College of Medicine; D.K. MacCarter, MD, Department of Rheumatology, North Valley Hospital; A.L. Pangan, MD, Immunology Clinical Development, AbbVie Inc.; X. Wang, PhD, Data and Statistical Sciences, AbbVie Inc.; J. Kalabic, MD, Pharmaceutical Development, AbbVie Deutschland GmbH & Co. KG; V.K. Ranganath, MD, Division of Rheumatology, University of California at Los Angeles. Address correspondence to Dr. V.K. Ranganath, UCLA Division of Rheumatology, Rehabilitation Building, 1000 Veteran Avenue, Rm 32-59, University of California at Los Angeles, Los Angeles, California 90095, USA. E-mail: vranganath@mednet.ucla.edu. Accepted for publication April 20, 2018.
Article Figures & Data
Additional Files
Data Supplement
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate
Gurjit S. Kaeley, Daryl K. MacCarter, Aileen L. Pangan, Xin Wang, Jasmina Kalabic, Veena K. Ranganath
The Journal of Rheumatology Sep 2018, jrheum.171232; DOI: 10.3899/jrheum.171232
Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate
Gurjit S. Kaeley, Daryl K. MacCarter, Aileen L. Pangan, Xin Wang, Jasmina Kalabic, Veena K. Ranganath
The Journal of Rheumatology Sep 2018, jrheum.171232; DOI: 10.3899/jrheum.171232